Hearing on Food and Drug Administration Activities.
Continuation of hearing to review FDA regulation of oral contraceptives, particularly the new drug Demulen, to examine FDA drug approval process and labeling regulations, and to review research on possible health risks of oral contraceptives containing high dosages of estrogen.
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Washington :
U.S. G.P.O.],
1970.
|
| Subjects: | |
| Online Access: | Electronic resource (PDF) |
| Summary: | Continuation of hearing to review FDA regulation of oral contraceptives, particularly the new drug Demulen, to examine FDA drug approval process and labeling regulations, and to review research on possible health risks of oral contraceptives containing high dosages of estrogen. |
|---|---|
| Item Description: | Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection(last viewed July 2018). Reuse except for individual research requires license from ProQuest, LLC. Electronic resource. |
| Physical Description: | 93 pages, digital, PDF file. |
| Format: | System requirements: PDF reader software. |